PubRank

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)

Clinical Trial ID NCT03683277

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03683277

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International uniform response criteria for multiple myeloma. Leukemia 2006 17.78
2 A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003 16.11
3 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 8.77
4 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007 8.41
5 Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007 5.55
6 Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003 4.67
7 Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2011 4.47
8 Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011 4.00
9 Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012 3.93
10 Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011 3.07
11 Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010 2.75
12 Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005 2.54
13 Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003 2.28
14 Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009 2.07
15 Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 2013 2.06
16 Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2012 1.91
17 In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011 1.85
18 Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2006 1.79
19 Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012 1.60
20 Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2012 1.56
21 Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013 1.51
22 Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007 1.48
23 Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005 1.22
24 Review of molecular diagnostics in multiple myeloma. Expert Rev Mol Diagn 2007 0.90
Next 100